title: Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
abstract: Low molecular weight heparins (LMWHs) are used for prevention of clotting in the dialysis circuit. The aim of this trial was to define the optimal dose of a new LMWH and to test the efficiency of a single dose at the start of the session. Fifteen patients were treated according to a double blind and crossover design during 4 blocks of 5 consecutive reviparin doses assigned randomly as 50, 60, 70, 85, and 100 IU anti-Xa/kg. Assessment was carried out on screening of fibrin rings or clots in the arterial and venous air traps and on visual detection of fiber in the dialyzer after rinsing. These clinical results were compared to plasmatic anti-Xa activity and thrombin-antithrombin (TAT) complex generation. A standard dose of 70 IU anti-Xa/kg of nadroparin was used as the control. After a bolus of 50 to 100 IU anti-Xa/kg, the occurrence of fibrin rings and clots in the air traps was dependent on three factors: dose of LMWH, time of the session, and patient status. A bolus of 85 IU anti-Xa/kg of reviparin was effective and safe for sessions of 4 h. For this dose, plasmatic anti-Xa activity was 0.96 +/- 0.28 IU/ml at Hour 2 and 0.82 +/- 0.22 IU/ml at Hour 4. TAT complexes are good markers of the activation of the coagulation. They did not increase during a 4 h session after a reviparin bolus of 100 IU/kg. For the same LMWH dose, the trial shows a great variability of the clinical effect and anti-Xa activities from one patient to another. A single dose of 85 IU anti-Xa/kg of reviparin can be used at the start of the dialysis session as a loading dose. We advise adapting the dose during the subsequent sessions according to the appearance of the blood circuit. The benefit of monitoring anti-Xa activity and TAT complexes could be tested in a further trial.
authors.affiliation: Department of Hemodialysis, Medical and Surgical Center, La Porte de Choisy, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Reach
authors.forename: N
authors.initials: N
authors.lastname: Luong
authors.forename: C
authors.initials: C
authors.lastname: Chastang
authors.forename: M
authors.initials: M
authors.lastname: Chakroun
authors.forename: S
authors.initials: S
authors.lastname: Mirshahi
authors.forename: M C
authors.initials: MC
authors.lastname: Mirshahi
authors.forename: J
authors.initials: J
authors.lastname: Soria
authors.forename: D
authors.initials: D
authors.lastname: Desmichels
authors.forename: A
authors.initials: A
authors.lastname: Baumelou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001780:Blood Coagulation Tests; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000008:administration & dosage*; D006435:Renal Dialysis / Q000379:methods*; D012680:Sensitivity and Specificity
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; C094240:reviparin